ES2149759T3 - Vacuna contra la enfermedad de lyme. - Google Patents

Vacuna contra la enfermedad de lyme.

Info

Publication number
ES2149759T3
ES2149759T3 ES91305971T ES91305971T ES2149759T3 ES 2149759 T3 ES2149759 T3 ES 2149759T3 ES 91305971 T ES91305971 T ES 91305971T ES 91305971 T ES91305971 T ES 91305971T ES 2149759 T3 ES2149759 T3 ES 2149759T3
Authority
ES
Spain
Prior art keywords
osp
lyme disease
burgdorferi
bacteria
mammals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91305971T
Other languages
English (en)
Inventor
William Marshall Acree
Bonnie Lee Wallace
Hsien-Jue Steve Chu
Lloyd George Chavez
David Scott Sandblom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Application granted granted Critical
Publication of ES2149759T3 publication Critical patent/ES2149759T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

ESTA INVENCION SE SUMINISTRA UNA VACUNA PARA PROTEGER A MAMIFEROS SUSCEPTIBLES DE LA ENFERMEDAD DE LYME, QUE CONSTA DE UN NUMERO DE LOS ANTEGENOS PRINCIPALES DE B. BURGDORFERI QUE SON EFECTIVOS PARA INDUCIR UN SUERO DE NEUTRALIZACION DE ANTICUERPOS CON LA B. BURGDORFERI. EL PROCESO PARA PREPARAR LA VACUNA CONSISTE EN CULTIVAR LA BACTERIA B. BURGDORFERI, CHEQUEANDO LOS NIVELES DE UNO DE LOS OSP A O OSP B, ACTIVANDO LA BACTERIA CUANDO SE OBTIENE UN MAXIMO EN LA PRODUCCION DE OSP A O OSP B, Y MEZCLANDO LA BACTERIA INACTIVADA EN UN PORTADOR BACTERIOLOGICAMENTE ACEPTABLE. ESTA INVENCION TAMBIEN INCLUYE UN PROCESO PARA INDUCIR LA ENFERMEDAD DE LYME EN MAMIFEROS DE LABORATORIO, QUE COMPRENDE LA INYECCION DEL VIRUS B. BURGDORFERI EN DICHOS MAMIFEROS DE MANERA QUE MINIMICE LOS EFECTOS DE LA TRANSMISION DE LA ENFERMEDAD.
ES91305971T 1990-07-06 1991-07-01 Vacuna contra la enfermedad de lyme. Expired - Lifetime ES2149759T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54919090A 1990-07-06 1990-07-06

Publications (1)

Publication Number Publication Date
ES2149759T3 true ES2149759T3 (es) 2000-11-16

Family

ID=24192007

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91305971T Expired - Lifetime ES2149759T3 (es) 1990-07-06 1991-07-01 Vacuna contra la enfermedad de lyme.

Country Status (11)

Country Link
EP (2) EP0465204B1 (es)
JP (1) JPH04297424A (es)
AT (1) ATE196425T1 (es)
AU (1) AU8014691A (es)
CA (1) CA2046025A1 (es)
DE (1) DE69132417T2 (es)
DK (1) DK0465204T3 (es)
ES (1) ES2149759T3 (es)
GR (1) GR3034460T3 (es)
IE (2) IE912303A1 (es)
PT (1) PT98202B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
US5217872A (en) * 1990-02-27 1993-06-08 The United States Of America As Represented By The Department Of Health And Human Services Method for detection of borrelia burgdorferi antigens
CA2057536C (en) * 1990-12-21 1999-10-26 John J. Dunn Cloning and expression of borrelia lipoproteins
US6221363B1 (en) * 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
DK0598816T3 (da) * 1991-08-15 1999-11-22 Deutsches Krebsforsch Osp A-proteiner fra Borrelia Burgdorferi-undergrupper, hvilke proteiner koder for gener og vacciner
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
ATE329615T1 (de) * 1994-04-11 2006-07-15 Wyeth Corp Borrelia burgdorferi bacterin
DE19629543C2 (de) * 1996-07-22 1999-02-11 Immuno Ag Immunassay zum Nachweis von anti-B. burgdorferi Antikörpern und Verfahren zur Serodiagnose bei Lyme Borreliose, diagnostische Mittel und Testkits zur Durchführung der Verfahren
US6368603B1 (en) * 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
EP1012181B1 (en) 1997-06-30 2006-08-23 The Administrators Of The Tulane Educational Fund Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
US6475492B1 (en) * 1999-04-28 2002-11-05 The Administrators Of The Tulane Educational Fund Peptides and assays for the diagnosis of lyme disease
PT1311540E (pt) 2000-08-18 2008-03-20 Univ New York State Res Found Ospa de borrelia burgdorferi modificada
HRP20050660A2 (en) * 2003-01-29 2006-02-28 Pfizer Products Inc. Canine vaccines against bordetella bronchiseptica
US20050202046A1 (en) * 2004-03-11 2005-09-15 Wyeth Canine vaccine for protection against ehrlichiosis
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
CN101573135B (zh) 2006-11-03 2013-06-12 先灵-普劳有限公司 犬莱姆病疫苗
EP3447064A1 (en) 2012-02-01 2019-02-27 Biopeptides Corporation Diagnostic peptides for lyme disease
WO2015085323A1 (en) 2013-12-06 2015-06-11 Biopeptides Corp. Peptides for diagnosing lyme disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4721617A (en) * 1986-08-14 1988-01-26 Regents Of The University Of Minnesota Vaccine against lyme disease
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
DE3942728C1 (en) * 1989-12-22 1991-05-23 Mikrogen Molekularbiologische Entwicklungs-Gmbh, 8000 Muenchen, De New immunologically active proteins derived from Borelia burgdorferiensity polyethylene vessel and a high density polyethylene sealing cap - useful as vaccine and for quick accurate diagnosis of Borelia infections
DE69122240T2 (de) * 1990-03-05 1997-02-13 The United States of America, represented by the Secretary, U.S. Department of Commerce, Washington, D.C. Antigen-wirkende proteine von borrelia burgdorferi
SG47447A1 (en) * 1990-06-15 1998-04-17 Univ Yale Compositions and methods for the prevention and diagnosis of lyme disease
EP0617680B1 (de) 1992-08-21 1998-11-25 BÄCHTIGER, Rolf Kettengetriebe mit veränderlichem übersetzungsverhältnis und zahnkette

Also Published As

Publication number Publication date
DE69132417T2 (de) 2001-05-23
EP0465204B1 (en) 2000-09-20
IE20010565A1 (en) 2002-07-10
PT98202B (pt) 1999-02-26
EP1016416A3 (en) 2002-10-23
JPH04297424A (ja) 1992-10-21
AU8014691A (en) 1992-01-09
ATE196425T1 (de) 2000-10-15
PT98202A (pt) 1992-05-29
DE69132417D1 (de) 2000-10-26
EP0465204A2 (en) 1992-01-08
GR3034460T3 (en) 2000-12-29
CA2046025A1 (en) 1992-01-07
EP0465204A3 (en) 1993-03-10
IE912303A1 (en) 1992-01-15
EP1016416A2 (en) 2000-07-05
DK0465204T3 (da) 2000-10-09

Similar Documents

Publication Publication Date Title
ES2149759T3 (es) Vacuna contra la enfermedad de lyme.
IT8026675A0 (it) Sorgente di luce incapsulata con guida di fibra accoppiata.
ES2096639T3 (es) Derivados de benzofurano, benzotiofeno, indol o indolizina, su procedimiento de preparacion, asi como las composiciones que los contienen.
ES2060611T3 (es) Fotoiniciadores correactivos.
GT197746150A (es) Nuevos agentes antielminticos y proceso para su prepracion
DK0654078T3 (da) Thrombinblodfraktion til anvendelse i en medicinsk procedure
ATE75608T1 (de) Arzeimittel.
ES8206192A1 (es) Procedimiento de preparar agentes para la embolizacion qui- rurgica
ES2078216T3 (es) Metodo para preparar copolimeros radiales asimetricos.
ES2131842T3 (es) Compuestos de triazol y su empleo como ligandos de dopamina-d3.
ES2109482T3 (es) Polimeros que contienen fluor y su preparacion y empleo.
AR010583A1 (es) CULTIVO DE CÉLULAS DE UNA CEPA DERIVADA DE UNA CEPA PROGENITORA DE UNA ESPECIE DE NEOSPORA, VACUNA QUE LAS CONTIENE, Y COMPOSICIoN.
ES2113891T3 (es) Anticuerpos monoclonales de raton.
ES2120034T3 (es) Dispersion de elastomero/fibra de aramida.
ES2103733T3 (es) Procedimiento para combatir el piojo de los peces.
ES2140373T3 (es) Nuevos depsipeptidos ciclicos citotoxicos a partir del trididemnum solidum.
ES2116612T3 (es) Nuevas bis-naftalimidas para el tratamiento del cancer.
ES2082029T3 (es) Conjugados de acido difluoroglutamico con foliatos y antifoliatos para el tratamiento de enfermedades neoplasticas.
ES2146226T3 (es) Utilizacion de una composicion celular para el tratamiento de los organismos humanos o animales.
FR2340981A1 (fr) Procede de solubilisation
ES2083418T3 (es) Preparaciones polimeras acuosas.
ES2033819T3 (es) Un procedimiento para preparar compuestos para uso en terapia.
ES2125879T3 (es) Triazaespirodecanona-metilcromanos para el tratamiento de enfermedades del sistema nervioso central.
ES2138976T3 (es) Uso de analogos o antagonistas de interleucina-10 para tratar la toxicidad inducida por endotoxinas o superantigenos.
ES2053535T3 (es) Derivados heterociclicos de cinco miembros de n,n'-diacilhidrazinas n' sustituidas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 465204

Country of ref document: ES